AAGHOTCPharmaceutical PreparationsFiscal year ends June 30

America Great Health

Financials through Q3 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 6, 2026

$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $12.69M
P/E (TTM): –
Dividend yield: –

America Great Health balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30	FY 2011 2011-06-30
Cash & Equivalents	0.04	0.05	0.05	0.06	0.40	0.00	0.00	0.00	0.00	0.00	0.02	–	0.02	0.00	0.01
Cash & Short-Term Investments	0.04	0.05	0.05	0.06	0.40	0.00	0.00	0.00	0.00	0.00	0.02	–	0.02	0.00	0.01
Receivables	0	0.06	0	0.00	0	–	–	–	–	–	–	–	–	–	–
Inventory	0.16	0.08	0.11	0.12	0.01	0.00	0	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	0.03	0.03	0.02	–	–	–	–	–	–	–	–	–	–	–	–
Total Current Assets	0.24	0.23	0.18	0.20	0.48	0.00	0.00	0.00	0.00	0.25	0.02	–	0.02	0.00	0.01
Property, Plant & Equipment	0.03	0.04	0.06	0.02	0.01	0	–	–	–	–	–	–	–	–	–
Gross Property, Plant & Equipment	–	–	0.07	–	–	–	–	–	–	–	–	–	–	–	–
Accumulated Depreciation	-0.05	-0.03	-0.02	–	–	–	–	–	–	–	–	–	–	–	–
Long-Term Investments	–	–	–	–	–	–	0	0.01	0	–	–	–	–	–	–
Equity Method Investments	–	–	–	–	–	–	–	0.01	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.03	0.04	0.04	0.09	0.13	0	–	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.03	0.04	0.01	0.01	0.00	–	–	–	–	–	–	–	–	–	–
Total Assets	0.30	0.32	0.30	0.34	0.62	0.00	0.00	0.01	0.00	0.25	0.02	–	0.02	0.00	0.01
Accounts Payable	1.49	1.44	1.45	1.44	0.06	0.05	0.04	0.02	0.01	0.00	0.08	0.01	0.01	0.01	0.01
Accrued Expenses	–	–	–	–	–	–	–	–	0.01	0	–	–	–	–	–
Short-Term Debt	0.60	0.61	0.73	0.18	0	–	–	–	–	–	–	–	–	–	–
Current Debt	0.60	0.61	0.73	0.18	0	–	–	–	–	–	–	–	–	–	–
Current Portion of Leases	0.03	0.02	0.04	0.07	0.05	0	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	0.00	0.00	0.00	0.00	0	0.00	0.00	0	–	–	–	–	–	–	–
Deferred Revenue (Current)	0.08	0.06	0.07	0.16	0	0	–	–	–	–	–	–	–	–	–
Other Current Liabilities	1.25	1.11	0.43	0.57	–	–	–	–	–	–	–	–	–	–	–
Total Current Liabilities	3.82	3.59	2.96	2.76	0.43	0.22	0.17	0.12	0.05	0.17	0.48	0.04	0.06	0.06	0.01
Long-Term Debt	2.22	1.83	1.52	1.03	0.58	–	–	–	–	–	–	–	–	–	–
Long-Term Leases	0	0.02	0	0.02	0.08	0	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.03	0.04	0.04	0.09	0.13	0	–	–	–	–	–	–	–	–	–
Total Liabilities	6.05	5.45	4.67	4.20	1.09	0.22	0.17	0.12	0.05	1.34	1.02	–	0.25	0.06	0.01
Total Debt	2.82	2.44	2.25	1.22	0.58	–	–	–	–	–	–	–	–	–	–
Preferred Stock	0	0	0	0	0	0	0	0	0	0.50	–	–	–	–	–
Common Stock	0	0	0	0	0	0	0	0	0	0	–	–	0.05	0.02	0.02
Additional Paid-In Capital	5.12	5.02	4.73	4.62	3.09	3.07	3.07	3.06	3.06	0.55	–	–	–	–	–
Retained Earnings	-11	-10	-9.03	-8.42	-3.56	-3.29	-3.23	-3.17	-3.11	-2.14	-1.00	-0.35	-0.19	-0.08	0.02
Treasury Stock	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Comprehensive Income & Other	0.00	0.00	0.00	0.00	0	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	-5.66	-5.04	-4.30	-3.80	-0.47	-0.22	-0.17	-0.11	-0.05	-1.09	-0.99	-0.35	-0.23	-0.06	0.00
Noncontrolling Interest	-0.08	-0.08	-0.07	-0.06	0	–	–	–	–	–	0.01	–	–	–	–
Total Equity	-5.74	-5.13	-4.18	-3.71	-0.47	-0.22	-0.17	-0.11	-0.05	-1.09	-0.99	-0.35	-0.23	-0.06	0.00
Total Liabilities & Equity	0.30	0.32	0.30	0.34	0.62	0.00	0.00	0.01	0.00	0.25	0.02	–	0.02	0.00	0.01
Shares Outstanding(shares)	21,153	21,137	21,107	21,090	21,071	20,236	20,236	20,236	20,236	20,056	19,981	19,981	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, TTM

Gross margin: 68.6%
Operating margin: -105.2%
Net margin: 175.9%
Return on equity, FY2025: 13.4%

Financial strength

Current ratio: 0.06
Debt to equity: -0.65
Debt to assets: 1864.3%
Cash to current liabilities: 1.1%

Valuation

P/E ratio: –
Price to sales: 34.93
Price to book: –
Dividend yield: –